Zobraziť v EDS

Towards prevention of diabetic peripheral neuropathy: clinical presentation, pathogenesis, and new treatments

Uložené v:
Podrobná bibliografia
Názov: Towards prevention of diabetic peripheral neuropathy: clinical presentation, pathogenesis, and new treatments
Autori: Melissa A Elafros, Henning Andersen, David L Bennett, Masha G Savelieff, Vijay Viswanathan, Brian C Callaghan, Eva L Feldman
Zdroj: Elafros, M A, Andersen, H, Bennett, D L, Savelieff, M G, Viswanathan, V, Callaghan, B C & Feldman, E L 2022, 'Towards prevention of diabetic peripheral neuropathy : clinical presentation, pathogenesis, and new treatments', The Lancet Neurology, vol. 21, no. 10, pp. 922-936. https://doi.org/10.1016/S1474-4422(22)00188-0
Informácie o vydavateľovi: Elsevier BV, 2022.
Rok vydania: 2022
Predmety: Metabolic Syndrome, 03 medical and health sciences, 0302 clinical medicine, Diabetes Mellitus, Type 2, Diabetic Neuropathies, Diabetic Neuropathies/diagnosis, Diabetes Mellitus, Type 2/complications, Quality of Life, Humans, Pain, Pain/etiology, Metabolic Syndrome/complications, 3. Good health
Popis: Diabetic peripheral neuropathy (DPN) occurs in up to half of individuals with type 1 or type 2 diabetes. DPN results from the distal-to-proximal loss of peripheral nerve function, leading to physical disability and sometimes pain, with the consequent lowering of quality of life. Early diagnosis improves clinical outcomes, but many patients still develop neuropathy. Hyperglycaemia is a risk factor and glycaemic control prevents DPN development in type 1 diabetes. However, glycaemic control has modest or no benefit in individuals with type 2 diabetes, probably because they usually have comorbidities. Among them, the metabolic syndrome is a major risk factor for DPN. The pathophysiology of DPN is complex, but mechanisms converge on a unifying theme of bioenergetic failure in the peripheral nerves due to their unique anatomy. Current clinical management focuses on controlling diabetes, the metabolic syndrome, and pain, but remains suboptimal for most patients. Thus, research is ongoing to improve early diagnosis and prognosis, to identify molecular mechanisms that could lead to therapeutic targets, and to investigate lifestyle interventions to improve clinical outcomes.
Druh dokumentu: Article
Jazyk: English
ISSN: 1474-4422
DOI: 10.1016/s1474-4422(22)00188-0
Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/36115364
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10112836/pdf/nihms-1884395.pdf
http://www.scopus.com/inward/record.url?scp=85138043741&partnerID=8YFLogxK
https://doi.org/10.1016/S1474-4422(22)00188-0
https://pure.au.dk/portal/en/publications/0002fac9-88ff-4965-96fd-621459688a18
Rights: Elsevier TDM
Prístupové číslo: edsair.doi.dedup.....d40bd5d9dbcaf2d71435827d17c60fb9
Databáza: OpenAIRE
Popis
Abstrakt:Diabetic peripheral neuropathy (DPN) occurs in up to half of individuals with type 1 or type 2 diabetes. DPN results from the distal-to-proximal loss of peripheral nerve function, leading to physical disability and sometimes pain, with the consequent lowering of quality of life. Early diagnosis improves clinical outcomes, but many patients still develop neuropathy. Hyperglycaemia is a risk factor and glycaemic control prevents DPN development in type 1 diabetes. However, glycaemic control has modest or no benefit in individuals with type 2 diabetes, probably because they usually have comorbidities. Among them, the metabolic syndrome is a major risk factor for DPN. The pathophysiology of DPN is complex, but mechanisms converge on a unifying theme of bioenergetic failure in the peripheral nerves due to their unique anatomy. Current clinical management focuses on controlling diabetes, the metabolic syndrome, and pain, but remains suboptimal for most patients. Thus, research is ongoing to improve early diagnosis and prognosis, to identify molecular mechanisms that could lead to therapeutic targets, and to investigate lifestyle interventions to improve clinical outcomes.
ISSN:14744422
DOI:10.1016/s1474-4422(22)00188-0